Home
Pain Therapeutics

This year's Pain Therapeutics event will be a great platform to explore new discoveries in the field. Speakers will share case studies and attendees will have the opportunity to explore new ways to overcome challenges in the development and administration of pain therapeutics. The programme will reflect and hopefully exceed the high standard set by last year's conference.

 

  • Dr John B. Davis, Senior Scientist, Pain and Neuroexcitability Disorders DPU, GlaxoSmithKline
  • Dr Aldemar Degroot, Senior Scientist, Exploratory Development Department, Astellas
                

Conference agenda

clock

9:00

Registration and Coffee

clock

9:30

Introduction

clock

9:40

Routes and Formulations of Analgesic Delivery

Exploring the latest innovative methods of drug delivery .

clock

10:20

Use of Nanotechnology for Drug Delivery in Pain Management

The use of nanoparticles to refine drug delivery and enhance the efficacy and safety of pain therapeutics.

clock

11:00

Morning Coffee

clock

11:30

Delivery of Analgesics to the Brain Across the Blood-Brain Barrier

Identifying a lack of penetration of the blood-brain barrier as the cause of failure of drugs acting on the central nervous system. 

clock

12:10

Cell and gene therapies for pain

Using cell and gene therapied for in vivo release of analgesics

clock

12:40

Discussion

Questions and problems from the auditorium

clock

13:00

Close of Workshop

clock

8:30

Registration & Cofee

clock

9:00

Chaiman's Opening Remarks

Praveen Anand

Praveen Anand, Professor of Clinical Neurology, Imperial College London

clock

9:10

LOST IN TRANSLATION: PRECLINICAL OUTCOME MEASURES AND HUMAN EXPERIMENTAL TRIALS IN PAIN RESEARCH

Aldemar Degroot

Aldemar Degroot, Translational Scientist, Astellas Pharma Europe

  • Additional outcome measures in preclinical models
  • Novel models to enhance translational science
  • Human experimental models and translational science
  • Translational science and pain
  • clock

    9:50

    TRPV1 AGONIST APPROACHES TO LOCALIZED MANAGEMENT OF CHRONIC PAIN

  •  Bases of nociceptor overactivity
  •  Expression of TRPV1 in hyperactive nociceptors
  • TRPV1 agonist-induced defunctionalization
  • Phase 3 clinical data for neuropathic pain
  • Keith Bley

    Keith Bley, Senior Vice President, Nonclinical R & D, NeurogesX

    Jeffrey Tobias

    Jeffrey Tobias, Chief Medical Officer, NeurogesX

    clock

    10:30

    Morning Coffee

    clock

    11:00

    TRPV1 AGONIST AND ANTAGONIST APPROACHES FOR THE TREATMENT OF PAIN

    Daniel Ursu

    Daniel Ursu, Research Scientist - Pain-Migraine DHT, Eli Lilly & Company

  •  Overview on agonist vs. antagonist approaches
  •  Topical vs. systemic application of TRPV1 agonist
  •  TRPV1 agonists: mechanism of action
  •  Pungency prediction of TRPV1 agonists
  • clock

    11:40

    TRPA1 AS A TARGET FOR THE TREATMENT OF PAIN

    Stuart Bevan

    Stuart Bevan , Professor of Pharmacology, Kings College London

  • Functions of TRPA1
  • Lessons from TRPA1 knockout mice
  • Effects of pharmacological intervention
  • clock

    12:20

    Networking Lunch

    clock

    13:40

    ADVANCES IN TRANSLATIONAL STRATEGIES FOR CHRONIC NEUROPATHIC PAIN

    Praveen Anand

    Praveen Anand, Professor of Clinical Neurology, Imperial College London

  • Non-invasive objective technique to assess hypersensitive / regenerating nerve fibres
  • Novel skin biopsy selective markers of hypersensitive / regenerating fibres 
  •  Mechanism-based cohorts in genetic, inflammatory, toxic, metabolic neuropathies
  • Human DRG culture models for novel drug development
     
  • clock

    14:20

    TRPM8 AGONISTS FOR PAIN TREATMENT

    Rory Mitchell

    Rory Mitchell, Wellcome Trust Fellow , University of Edinburgh

  • The effect of TRPM8 agonists sensory sensitivity in neuropathic and inflammatory chronic pain models
  • Mechanism of action
  • Topical route of application
  • clock

    15:00

    Afternoon Tea

    clock

    15:20

    PITFALLS AND CHALLENGES IN ANIMAL MODELLING OF PAIN

    Odd-Geir Berge

    Odd-Geir Berge, Senior Principal Scientist, AstraZeneca

  •  Confounds of measurement
  •  What’s measured isn’t always what it seems
  •   Bias towards (false) positive outcomes
  •  How do we choose methods and approaches?
  •  Translation across species
  •  Is the rat just a small man, the mouse a small rat?
  • A way forward?
  • clock

    16:00

    MINIMISING THE RISKS IN PAIN DRUG DEVELOPMENT

    Paul Passier

    Paul Passier, Associate Scientific Director Exploratory Medicine, Astellas Pharma Europe

  • Strategies in early clinical development (first in man through PoC) to minimize this risk
  • Models involved, examples and flaws of the approach and their contribution to risk reduction
  • How to improve predictability of the dose range and regimen in patients
  • Can we improve responder rate?
  • clock

    16:40

    TRANSLATIONAL NEUROPHYSIOLOGICAL BIOMARKERS FOR DRUG DISCOVERY OF ANALGESIC DRUGS

    Martin Koltzenburg

    Martin Koltzenburg, Chair of Clinical Neurophysiology and Deputy Director, Centre for Neuromuscular Disease

  • Ion channel expression in peripheral nociceptors
  • Role of sodium channels for perception of pain
  • Noninvasive analysis of ion channel properties
  • Nerve excitability studies is a new translational biomarker

     

  • clock

    17:20

    Chaiman's Closing Remarks and Close of Day One

    clock

    8:30

    Registration & Cofee

    clock

    9:00

    Chairman's Opening Remarks

    Jonathan  Stewart

    Jonathan Stewart, Director, Neurology MDC, EU Clinical, GlaxoSmithKline

    clock

    9:10

    TARGETING VOLTAGE-GATED SODIUM CHANNELS FOR PAIN THERAPY

    Steve England

    Steve England, Associate Research Fellow, Pain Therapeutics, Pfizer

  • Sodium channels in pain signalling
  • Validation of Nav channels as targets for pain therapy
  •  Challenges to the delivery of new Nav channel modulators
  •  Emerging Nav pharmacology
  • clock

    9:50

    WHY WERE WE NOT ABLE TO DELIVER BETTER MEDICINES FOR CHRONIC PAIN?

    Joachim Scholpp

    Joachim Scholpp, Director Exploratory Clinical Science, Nycomed

  • Efficacy of currently available medicines
  • Factors determining efficacy
  • Factors determining successful clinical trials
  • Key factors for better medicines
  • clock

    10:30

    Morning Coffee

    clock

    11:00

    PROSTANOID EP4 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE PAIN

    Karen Maubach

    Karen Maubach, Clinical Development Executive, BTG

  • EP4 receptor antagonists
  • Alleviating the symptoms of migraine after an attack
  • BGC20-1531 side-effect profile
  • Neurogenic and inflammatory pain paradigm
     
  • clock

    11:40

    INNOVATIONS: PAIN THERAPEUTICS DELIVERY

    Kewal Jain

    Kewal Jain, Chief Executive Officer, Jain PharmaBiotech

  •  Routes and formu;lations
  • Drug delivery
  • Cell and gene therapies
  • clock

    12:20

    Networking Lunch

    clock

    13:50

    MONOAMINE REUPTAKE INHIBITORS - A DISCUSSION OF OCCUPANCY-RESPONSE RELATIONSHIPS FROM PRECLINICAL MODELS TO CLINICAL ANALGESICS

    Jan  Smith

    Jan Smith, Director, Theravance

  • Rationale for monoamine reuptake inhibition
  • Monoamine reuptake inhibitors - preclinical occupancy-response relationships
  • Monoamine reuptake inhibitors - efficacy in chronic pain states
  • clock

    14:30

    TARGETING GLIAL CELLS FOR THE TREATMENT OF PAIN

    John Davis

    John Davis , Director, Biology Pain & Neuroexcitability DPU, GlaxoSmithKline

  • Neuronal-glial interactions in pain
  • Role of glia in the central control of pain
  • Therapeutic targets on glia
  • clock

    15:10

    CB2 RECEPTOR SELECTIVE AGONISTS IN TREATMENT OF PAIN – FROM SCREENING TO CLINICAL TRIALS

    Neelima Khairatkar-Joshi

    Neelima Khairatkar-Joshi, Vice President and Head, In vitro Biology, Glenmark Research Centre, India

  • Cannabinoids in pain management – Historical perspective
  • CB2 receptor target Biology
  • Screening and CB2 receptor agonist lead identification
  • Efficacy in animal models of pain
  • Clinical trials
  • clock

    15:50

    Chairman's Closing Remarks

    clock

    16:00

    Afternoon Tea and Close of Conference

    Workshops

    INNOVATIONS IN DELIVERY OF THERAPEUTICS FOR PAIN

    INNOVATIONS IN DELIVERY OF THERAPEUTICS FOR PAIN

    Copthorne Tara Hotel
    10 June 2009
    London, United Kingdom

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download

    Title


    Description

    Download

    Title


    Description


    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SAE Media Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@saemediagroup.com

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    Group Booking

    Please complete the below form and a member of SAE Media Group’s booking team will be in contact within 24 hours

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SAE Media Group

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SAE Media Group , Ground Floor, India House, 45 Curlew Street, London, SE1 2ND, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smgconferences.com Email: events@saemediagroup.com
    Registered in England - SMi Group Ltd trading as SAE Media Group




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.

    Thank you for visiting our event

    If you would like to receive further information about our events, please fill out the information below.

    By ticking above you are consenting to receive information by email from SAE Media Group.
    Full details of our privacy policy can be found here https://www.smgconferences.com/privacy-legals/privacy-policy/.
    Should you wish to update your contact preferences at any time you can contact us at data.privacy@smgconferences.com.
    Should you wish to be removed from any future mailing lists please click on the following link http://www.smgconferences.com/opt-out

    Fill in your details to download the brochure

    By submitting this form you agree to our privacy policy and consent to receiving communications, you may opt out at any time.